---
title: "AbbVie's new HIV drug Class 1 approved for clinical trials in China"
description: "On July 29th, the China National Medical Products Administration's Center for Drug Evaluation (CDE) website announced that AbbVie's Class 1 new drug ABBV-382 injection has been approved for clinical t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/210055647.md"
published_at: "2024-07-29T06:04:03.000Z"
---

# AbbVie's new HIV drug Class 1 approved for clinical trials in China

> On July 29th, the China National Medical Products Administration's Center for Drug Evaluation (CDE) website announced that AbbVie's Class 1 new drug ABBV-382 injection has been approved for clinical trials. It is intended to be developed for the continuous suppression of immune-mediated HIV (HIV plasma viral load at undetectable levels) without combination antiretroviral therapy (ART). Public information shows that ABBV-382 is an α4β7 integrin monoclonal antibody, currently in phase 2 clinical trials globally. This is the first time this investigational drug has been approved for clinical trials in China. According to AbbVie's official website, the company is developing a combination of ABBV-181 (budigalimab, anti-PD-1) and ABBV-382 (research code: ABBV-1882), studying it as an HIV virus control regimen for antiretroviral therapy (ART), currently in phase 2 clinical trials

According to the Zhitong Finance and Economics APP, on July 29th, the China National Medical Products Administration Drug Evaluation Center (CDE) official website announced that AbbVie (ABBV.US) Class 1 new drug ABBV-382 injection was approved for clinical trials. It is intended to be developed for the continuous suppression of immune-mediated HIV (HIV plasma viral load at undetectable levels) without combination antiretroviral therapy (ART). Public information shows that ABBV-382 is an α4β7 integrin monoclonal antibody, currently in phase 2 clinical trials globally, and this is the first time this investigational drug has been approved for clinical trials in China.

![Image](https://imageproxy.pbkrs.com/http://img.zhitongcaijing.com/images/contentformat/3207592534a5c0c5ba703f3e6252bac9.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

According to AbbVie's official website, the company is developing a combination of ABBV-181 (budigalimab, anti-PD-1) and ABBV-382 (research code: ABBV-1882), studying it as an antiretroviral therapy (ART) for HIV virus control, currently in phase 2 clinical trials

### Related Stocks

- [ABBV.US - Abbvie](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 艾伯维｜8-K：2025 财年营收 612 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/274816008.md) |
| 艾伯维在腹壁疝气试验中推进新的毒素疗法：投资者应关注哪些方面 | 艾伯维（AbbVie，股票代码：ABBV）正在进行一项针对 AGN-151607-DP 的二期临床试验，该疗法基于肉毒毒素，旨在改善腹股沟疝手术的结果。该研究评估了该药物在促进主要筋膜闭合而无需复杂修复技术方面的安全性和有效性。试验约有 2 | [Link](https://longbridge.com/en/news/275926867.md) |
| 沃尔玛四季度财报超预期但盈利指引不及预期，CEO 称 “美国低收入家庭只能勉强维持生计” | 沃尔玛 Q4 营收超预期，新财年盈利指引（每股 2.75-2.85 美元）远低于市场预期的 2.96 美元，显示通胀压力下消费者支出不确定性犹存，拖累股价下跌 1.38%。财报印证 K 型” 分化：高收入家庭驱动增长，低收入群体 “钱包吃紧 | [Link](https://longbridge.com/en/news/276398633.md) |
| 谷歌突然发布 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌发布了最新的大模型 Gemini 3.1 Pro，其推理性能较去年发布的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 评测中，Gemini 3.1 Pro 得分 77.1%，显示出强大的推理能力。新模型支持多源数据综合和复杂 | [Link](https://longbridge.com/en/news/276396515.md) |
| 学习英伟达刺激芯片销售，AMD 为 “AI 云” 借款做担保 | AMD 为扩大市场份额祭出金融 “狠招”！为初创公司 Crusoe 的 3 亿美元购芯贷款提供担保，承诺在其无客户时 “兜底” 租用芯片。这一复刻英伟达 “租卡云” 路径的策略虽能短期推高销量，但也令 AMD 在 AI 需求放缓时面临更大的 | [Link](https://longbridge.com/en/news/276401504.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.